Can an oral medication help control stubborn psoriasis without injections? Discover how apremilast works, what clinical studies reveal, and what patients should know before starting treatment.
Psoriasis is more than a cosmetic skin condition. For millions of people, persistent red or discolored plaques, scaling, itching and discomfort can interfere with sleep, confidence and everyday activities.
Topical creams and moisturizers may help manage mild symptoms, but people with more extensive or difficult-to-treat psoriasis sometimes need medication that works throughout the body.
One option is apremilast, the active ingredient in Otezla, an oral prescription treatment for certain forms of psoriasis and other inflammatory conditions.
Unlike injectable biologic therapies, conventional apremilast tablets are taken by mouth. But how well does the treatment actually work, and what improvements can patients realistically expect?
1. What Is Apremilast and How Does It Work?
Apremilast belongs to a class of medicines called phosphodiesterase 4 (PDE4) inhibitors.
PDE4 is an enzyme involved in regulating inflammatory signaling within immune cells. By inhibiting PDE4, apremilast helps modify inflammatory pathways associated with psoriasis.
This can reduce the inflammatory activity contributing to thickened, scaly skin plaques.
Importantly, apremilast is not a steroid, antibiotic or traditional injectable biologic.
It is an oral systemic treatment, meaning its effects are not limited to the skin area where symptoms appear.
Psoriasis is a chronic immune-mediated condition, so treatment generally focuses on controlling symptoms and improving quality of life rather than providing a permanent cure.
2. Who May Benefit From Apremilast?
Apremilast may be considered for people with plaque psoriasis who need treatment beyond topical creams.
In the United States, Otezla is approved for plaque psoriasis in adults who are candidates for phototherapy or systemic therapy. It is also approved for moderate-to-severe plaque psoriasis in eligible children aged six years and older.
European indications and treatment requirements differ, so prescribing decisions must follow local authorization and specialist assessment.
Patients may discuss apremilast when psoriasis affects substantial skin areas, causes persistent itching, involves difficult locations, or responds inadequately to topical treatment.
Apremilast is also used for active psoriatic arthritis, a condition involving joint inflammation associated with psoriasis.
The presence of joint pain, swelling or morning stiffness should be discussed with a clinician because untreated psoriatic arthritis can cause lasting joint damage.
3. How Effective Is Apremilast After 16 Weeks?
One of the most useful ways to evaluate psoriasis treatment is through clinical trial outcomes.
In the phase III ESTEEM studies, apremilast was compared with placebo in adults with moderate-to-severe plaque psoriasis.
Researchers measured improvements using the Psoriasis Area and Severity Index (PASI), a standardized assessment of psoriasis severity.
A PASI 75 response means that a patient's score has improved by at least 75% from baseline.
At week 16, approximately one-third of apremilast-treated patients achieved PASI 75 in major clinical studies.
This is a meaningful improvement for some patients, although it also shows that not everyone achieves substantial skin clearance.
Results vary depending on disease severity, individual response and other factors.
The practical takeaway: Apremilast can meaningfully improve psoriasis, but complete clearance is not guaranteed, and some patients may require another treatment approach.
4. Can Apremilast Help Scalp Psoriasis?
Scalp psoriasis can be especially frustrating because itching, flaking and visible scaling may persist despite shampoos or topical treatments.
In clinical studies involving patients with scalp psoriasis, apremilast improved scalp symptoms compared with placebo.
The American Academy of Dermatology reports that more than 40% of patients achieved clear or almost clear scalp psoriasis by week 16 in relevant clinical trial populations.
This makes scalp improvement an important potential benefit for patients considering oral treatment.
However, individual outcomes vary, and patients with severe scalp disease may require additional or alternative therapies.
5. What About Nail Psoriasis?
Nail psoriasis may cause pitting, discoloration, thickening, separation from the nail bed and discomfort.
It can also interfere with daily activities and may be associated with psoriatic arthritis.
Research from the ESTEEM trials found that apremilast improved nail psoriasis severity compared with placebo.
Some patients achieved at least a 50% improvement in nail psoriasis severity scores by week 16.
Nail improvements may take longer to become visible because fingernails and toenails grow slowly.
Patients should therefore avoid judging treatment success solely by the appearance of their nails after a few weeks.
6. Does Apremilast Reduce Psoriasis Itching?
Itching is often one of the most disruptive symptoms of psoriasis.
Even when plaques are not extensive, persistent itching can affect sleep, concentration and emotional well-being.
Clinical studies have demonstrated improvements in itching among patients receiving apremilast.
For some patients, reduced itching may be an important benefit even before they achieve their desired level of skin clearance.
Tracking itch severity alongside plaque appearance can provide a more complete picture of treatment response.
7. Apremilast vs Biologics: What Is the Difference?
Patients frequently compare apremilast with biologic medicines such as adalimumab, secukinumab or other treatments targeting specific inflammatory pathways.
The most obvious difference is how the medicines are administered.
Conventional apremilast is an oral tablet, whereas many biologic psoriasis treatments are administered by injection or infusion.
Another important difference is treatment effectiveness.
Several modern biologics achieve higher rates of near-complete or complete skin clearance than apremilast in clinical studies.
However, choosing a psoriasis treatment involves more than comparing clearance percentages.
Doctors also consider disease severity, psoriatic arthritis, medical history, safety, treatment preferences, access and cost.
Apremilast may appeal to some patients who prefer oral therapy, but it is not automatically safer or more appropriate for every individual.
8. How Is Apremilast Taken?
For adults using conventional immediate-release apremilast tablets, the usual maintenance dose is 30 mg twice daily, following a gradual initial dose-escalation schedule.
The first several days of treatment involve lower doses to help reduce gastrointestinal side effects.
The tablets can generally be taken with or without food and should be swallowed whole.
Patients with severe kidney impairment may require a lower dose.
Pediatric dosing is weight-based, and extended-release formulations have different dosing instructions.
Always follow the exact instructions for the prescribed formulation. Do not increase, reduce or stop treatment without consulting the prescribing clinician.
9. What Side Effects Should Patients Know About?
The most frequently reported adverse effects of apremilast include diarrhea, nausea, headache and upper respiratory tract infections.
Gastrointestinal symptoms are often more noticeable during the initial treatment period.
The prescribing information also highlights important precautions involving severe gastrointestinal symptoms, mood changes and weight loss.
Patients should contact their healthcare professional if they experience persistent or severe diarrhea, vomiting, unexplained significant weight loss, depression or other concerning symptoms.
New or worsening suicidal thoughts require urgent medical attention.
Certain medicines, including strong enzyme-inducing drugs such as rifampin, may reduce apremilast effectiveness.
Pregnancy, breastfeeding, kidney disease and other medical conditions should be reviewed before treatment.
10. When Should You Expect Results?
Patients often want to know whether apremilast works within days, weeks or months.
Although individual symptoms may begin improving earlier, week 16 is an important assessment point used in major clinical studies.
Skin plaques, scalp scaling, itching and nail changes may improve at different rates.
A clinician can help determine whether the response is sufficient to continue treatment or whether another strategy is needed.
Do not assume that a few weeks without dramatic improvement means treatment has failed.
At the same time, continuing an ineffective treatment indefinitely without reassessment is not ideal.
11. Practical Tips for Living With Psoriasis
Medication is only one part of long-term psoriasis management.
Regular moisturizing can help reduce dryness and improve skin comfort.
Gentle skincare, avoiding unnecessary scratching and identifying personal triggers may also help.
Stress, smoking, excessive alcohol consumption and certain infections can worsen psoriasis in some people.
Maintaining a healthy weight and managing associated conditions are also important.
People with psoriasis have increased risks of certain health problems, including psoriatic arthritis and cardiometabolic disease, making routine medical follow-up valuable.
These measures complement prescribed treatment rather than replace it.
12. Frequently Asked Questions
Is apremilast a steroid?
No. Apremilast is a PDE4 inhibitor, not a corticosteroid.
Is Otezla the same as apremilast?
Otezla is a brand name for medication containing apremilast. Availability of brands and formulations varies by country.
Can apremilast cure psoriasis permanently?
No. It can help control inflammation and symptoms, but psoriasis remains a chronic condition.
Is apremilast suitable for everyone with psoriasis?
No. Treatment suitability depends on psoriasis severity, medical history, age, other medications and local prescribing indications.
Can psoriasis return after stopping apremilast?
Yes. Symptoms can return after treatment discontinuation, so long-term management should be discussed with a healthcare professional.
Final Thoughts
Apremilast offers an oral treatment option for people whose psoriasis requires more than topical care.
Clinical evidence supports improvements in plaque psoriasis, scalp symptoms, nail involvement and itching, although response varies and some treatments achieve higher clearance rates.
For patients considering Otezla or another apremilast-containing medication, the most important step is an individualized discussion with a qualified healthcare professional.
The goal of psoriasis treatment is not simply clearer skin, but better comfort, daily functioning and long-term quality of life.
At Zarvypharm, we believe reliable, understandable medication information helps patients make better-informed healthcare decisions.
Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice. Apremilast is a prescription medication and should only be used under appropriate medical supervision.
References
-
U.S. FDA / DailyMed. Otezla (apremilast), prescribing information.
-
European Medicines Agency. Otezla, European product information.
-
American Academy of Dermatology. Psoriasis Treatment: Apremilast.
-
American Academy of Dermatology. Psoriasis Clinical Guidelines.
-
ESTEEM 1 and ESTEEM 2 investigators. Apremilast in nail and scalp psoriasis. Journal of the American Academy of Dermatology. DOI: 10.1016/j.jaad.2015.09.001.
